Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesMERCK Kommanditgesellschaft auf Aktien

MERCK Kommanditgesellschaft auf Aktien

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
170.0 USD 2.55 ( 1.52%)
Last update at 2026-11-04T14:34:00Z
VOLUME
200
Market Cap
66051.46M
P/E
24.86

Momentum Score

…

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a sub

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
170.00
Low
170.00
High
52 Week Price Range
112.78
Low
175.56
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Merck KGaA is a German multinational science and technology company operating in pharmaceuticals, life-science tools and services, and performance materials. Long-term growth may be supported by its biopharma pipeline and therapeutic launches, recurring revenue from lab consumables and services, and demand for specialty materials in electronics and displays. The company appears positioned to benefit from a diversified, R&D-led portfolio and a broad global commercial footprint.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
167.45
Dividend Yield
1.40%
Revenue TTM
21135.00M
Revenue Per Share
48.63
Gross Profit TTM
12488.00M
Debt / Equity
0.42
ROE
8.13%
Net Debt
9635.52M
ROCE
9.44%
Diluted EPS TTM
6.11

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 3306.76M 3536.00M 3484.00M 4287.00M 3924.00M
Minority interest -7.00M -9.00M -10.00M -14.00M -10.00M
Net income 2607.02M 2777.00M 2824.00M 3326.00M 3055.00M
Selling general administrative 1462.00M 1392.00M 1392.00M 1306.00M 1241.00M
Selling and marketing expenses 4032.00M 3968.00M 3914.00M 4097.00M 3714.00M
Gross profit 11886.55M 12485.00M 12435.00M 13705.00M 12336.00M
Reconciled depreciation 2298.00M 2134.00M 1880.00M 2030.00M 1762.00M
Ebit 4063.48M 3828.00M 3805.00M 4474.00M 4179.00M
Ebitda 5942.77M 5962.00M 5685.00M 6744.00M 5962.00M
Depreciation and amortization 1879.30M 2134.00M 1880.00M 2270.00M 1783.00M
Operating income 4063.48M 3645.00M 3609.00M 4474.00M 4179.00M
Other operating expenses 17030.62M 17511.00M 17384.00M 17480.00M 15491.00M
Interest expense 261.90M 292.00M 272.00M 235.00M 272.00M
Tax provision 693.00M 751.00M 650.00M 948.00M 859.00M
Interest income 93.00M 164.00M 172.00M 71.00M 46.00M
Net interest income -284.00M -139.00M -151.00M -164.00M -226.00M
Income tax expense 692.74M 751.00M 650.00M 948.00M 859.00M
Total revenue 21094.10M 21156.00M 20993.00M 22232.00M 19687.00M
Total operating expenses 7823.07M 8840.00M 8826.00M 8953.00M 8140.00M
Cost of revenue 9207.55M 8671.00M 8558.00M 8527.00M 7351.00M
Total other income expense net -756.72M -109.00M -125.00M -187.00M -255.00M
Net income from continuing ops 2615.00M 2785.00M 2834.00M 3339.00M 3065.00M
Net income applicable to common shares - - - 3326.00M 3055.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 52080.49M 51567.00M 48495.00M 48526.00M 45362.00M
Intangible assets 7659.13M 6282.00M 6551.00M 7300.00M 7612.00M
Other current assets 971.54M 2179.00M 1367.00M 151.00M 94.00M
Total liab 23431.22M 21580.00M 21740.00M 22521.00M 23946.00M
Total stockholder equity 28581.29M 29912.00M 26680.00M 25927.00M 21338.00M
Other current liab 6180.23M 6153.24M 4545.00M 6720.00M 839.00M
Common stock 564.79M 565.00M 565.00M 565.00M 565.00M
Capital stock 565.00M 565.00M 565.00M 565.00M 565.00M
Retained earnings 24005.01M 22086.00M 20634.00M 18463.00M 15134.00M
Other liab - - - 3808.00M 5244.00M
Good will 17927.28M 19152.00M 17845.00M 18415.00M 17004.00M
Other assets - 1.00M -627.00M 1730.00M 1932.00M
Cash 2328.00M 2149.00M 1982.00M 1398.00M 1511.00M
Total current liabilities 9038.61M 11294.00M 8699.00M 9513.00M 10432.00M
Current deferred revenue 215.92M - 249.00M - 5555.00M
Net debt 9635.52M 8122.00M 7959.00M 9000.00M 9255.00M
Short term debt 1221.00M 3273.00M 702.00M 1198.00M 2496.00M
Short long term debt 1098.00M 3136.00M 503.00M 1073.00M 2379.00M
Short long term debt total 11963.52M 10271.00M 9941.00M 10398.00M 10766.00M
Other stockholder equity 3812.57M 7261.00M 3814.00M 6899.00M 5639.00M
Property plant equipment - - - 8203.00M 7217.00M
Total current assets 13225.05M 13450.00M 12393.00M 12201.00M 10982.00M
Net tangible assets - - - 210.00M -3278.00M
Short term investments 597.00M 558.00M 431.00M 244.00M 112.00M
Net receivables 4768.21M 4080.00M 3976.00M 5776.00M 5365.00M
Long term debt 10206.00M 6373.00M 8846.00M 8834.00M 7928.00M
Inventory 4560.29M 4484.00M 4637.00M 4632.00M 3900.00M
Accounts payable 1421.47M 1502.00M 1770.00M 1595.00M 1542.00M
Accumulated other comprehensive income 198.93M 3224.71M 1667.00M - -
Non currrent assets other 277.90M 788.00M 1215.00M 432.00M 271.00M
Non current assets total 38855.44M 38116.00M 36102.00M 36325.00M 34380.00M
Capital lease obligations 648.00M 762.00M 515.00M 491.00M 459.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -3050.00M -1892.00M -2743.00M -200.00M
Change to liabilities - - - 101.00M 433.00M
Total cashflows from investing activities -4259.40M -3050.00M -1892.00M -2743.00M -1578.00M
Net borrowings 1677.00M 53.00M -568.00M -588.00M -1747.00M
Total cash from financing activities 627.76M -985.00M -1732.00M -1555.00M -2504.00M
Change to operating activities - - - -166.00M 75.00M
Net income 2607.02M 2786.00M 2824.00M 3339.00M 3065.00M
Change in cash 521.31M 535.00M 128.00M -45.00M 544.00M
Begin period cash flow 2217.67M 1982.00M 1854.00M 1899.00M 1355.00M
End period cash flow 2738.97M 2517.00M 1982.00M 1854.00M 1899.00M
Total cash from operating activities 3930.53M 4586.00M 3784.00M 4259.00M 4616.00M
Depreciation 1879.30M 2134.00M 1782.00M 2030.00M 1762.00M
Other cashflows from investing activities 1778.33M -581.00M -46.00M -1.00M -0.30M
Dividends paid 1038.61M 284.00M 1152.00M -239.00M -181.00M
Change to inventory -256.90M 36.00M -89.00M -604.00M -472.00M
Change to account receivables -165.94M 79.00M -8.00M -413.00M -310.00M
Other cashflows from financing activities -10.00M -754.00M -12.00M 3185.00M 283.00M
Change to netincome - - - 217.00M 128.00M
Capital expenditures 1583.41M 2184.00M 2023.00M 1806.00M 1421.00M
Change in working capital -813.70M -310.00M -707.00M -1082.00M -274.00M
Stock based compensation - - 2.00M - -
Other non cash items 257.90M -24.00M -117.00M -28.00M 63.00M
Free cash flow 2347.12M 2402.00M 1761.00M 2453.00M 3195.00M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 2.55
1.52%		 170.00 24.86 15.11 3.13 1.98 3.08 18.89
MKKGY
Merck KGaA ADR		 0.85
2.56%		 34.06 21.25 14.93 3.10 2.14 3.60 12.98
TAK
Takeda Pharmaceutical Co Ltd ADR		 0.31
1.49%		 21.06 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 40.91 - 10.66 0.01 1.16 2.94 23.11
TEVA
Teva Pharma Industries Ltd ADR		 -0.06
0.14%		 41.85 65.42 12.55 2.64 5.82 3.35 18.43

Profile*

MERCK Kommanditgesellschaft auf Aktien

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a sub

Frankfurter Strasse 250, Darmstadt, Germany, 64293

49 6151 72 0

https://www.emdgroup.com

62136

Name Title Year Born
Ms. Belen Garijo Lopez M.D. Chair of Exec. Board & CEO 1960
Dr. Marcus Kuhnert CFO & Member of Exec. Board 1968
Dr. Kai Beckmann CEO of Electronics & Member of the Exec. Board 1965
Mr. Peter Guenter CEO of Healthcare Bus. & Member of Exec. Board 1962
Dr. Matthias J. Heinzel CEO of Life Science Sector & Member of Exec. Board 1967
Mr. Gerhard Schmitz Head of Global Accounting 1963
Mr. Dirk Toepfer Chief Information Officer NA
Mr. Constantin Fest Head of Investor Relations 1977
Dr. Friederike Rotsch Group Gen. Counsel and Head of Group Legal & Compliance 1972
Ms. Barbara Weiland Chief Compliance Officer 1974

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…